Current Status and Prospect of PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy 
in Elderly Patients with Advanced NSCLC

The incidence of cancer is closely correlated with age, as 75% of non-small cell lung cancer (NSCLC) patients are aged at least 65 years. The availability of immune checkpoint inhibitors (ICIs) has altered the available NSCLC therapeutic pattern. Limited studies on elderly patients have demonstrated...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Yunye MAO, Shu SHENG, An WANG, Jinzhao ZHAI, Xiangwei GE, Di LU, Jinliang WANG
Hōputu:	Artigo
Reo:	Chinês
I whakaputaina:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2024-05-01
Rangatū:	Chinese Journal of Lung Cancer
Ngā marau:	lung neoplasms elderly non-small cell lung cancer immunosenescence immunotherapy immunotherapy combined with low-intensity chemotherapy
Urunga tuihono:	http://dx.doi.org/10.3779/j.issn.1009-3419.2024.106.10
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!